Erythrocyte deformability is impaired in sickle cell disease (SCD). The regulation of cytoskeletal protein organization plays a key role in erythrocyte deformability. The activation of adenylyl cyclase (AC)/cAMP/Protein kinase A (PKA) signaling pathway was associated with increased deformability in healthy erythrocytes, however the role of this pathway in SCD is unknown.
OBJECTIVE:
We evaluated mechanical responses of sickle red blood cells under physiological levels of shear stress and the possible link between their deformability and AC/cAMP/PKA signaling pathway.
METHODS:
The shearing of sickle red blood cells at physiological level (5 Pa) and the measurement of deformability were performed by a laser assisted optical rotational cell analyzer (LORRCA).
RESULTS:
Red blood cell deformability increased of 2.5–6.5% by blocking the activity of phosphodiesterase with Pentoxifylline (10μM) (p < 0.05). The inhibition of AC with SQ22536 (100μM) produced more significant rise in deformability (+4.8–12%, p < 0.01). No significant change was observed by the inhibition of PKA with H89 (10μM).
CONCLUSION:
Pentoxifylline and SQ22536 increased the deformability of sickle red blood cells under fluid shear stress. Modulation of the AC/cAMP/PKA pathway could have the potential to be an effective therapeutic approach for SCD through shear-induced improvements of RBC deformability.
KaulDK, FabryME, NagelRL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications. Proc Natl Acad Sci USA. 1989;86:3356–60.
4.
HebbelRP, BoogaertsMA, EatonJW, SteinbergMH. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med. 1980;302:992–5.
5.
KaulDK, FinneganE, BarabinoGA. Sickle red cell-endothelium interactions. Microcirculation. 2009;16:97–111.
6.
ChienS, UsamiS, BertlesJF. Abnormal rheology of oxygenated blood in sickle cell anemia. J Clin Invest. 1970;49(4):623–34.
7.
HuangZ, HearneL, IrbyCE, KingSB, BallasSK, Kim-ShapiroDB. Kinetics of increased deformability of deoxygenated sickle cells upon oxygenation. Biophys J. 2003;85(4):2374–83.
8.
ConnesP, RenouxC, RomanaM, AbkarianM, JolyP, MartinC, et al. Blood rheological abnormalities in sickle cell anemia. Clin Hemorheol Microcirc. 2018;68(2-3):165–72.
9.
EvansE, MohandasN, LeungA. Static and dynamic rigidities of normal and sickle erythrocytes. Major influence of cell hemoglobin concentration. J Clin Invest. 1984;73:477–88.
10.
NashGB, JohnsonCS, MeiselmanHJ. Mechanical properties of oxygenated red blood cells in sickle cell (HbSS) disease. Blood. 1984;63:73–82.
11.
BrandaoMM, FontesA, Barjas-CastroML, BarbosaLC, CostaFF, CesarCL, et al. Optical tweezers for measuring red blood cell elasticity: Application to the study of drug response in sickle cell disease. Eur J Haematol. 2003;70:207–11.
12.
ZhengY, CachiaMA, GeJ, XuZ, WangC, SunY. Mechanical differences of sickle cell trait (SCT) and normal red blood cells. Lab Chi. 2015;15:3138–46.
BallasSK. Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management. Clin Hemorheol Microcirc. 2018;68(2-3):105–28.
15.
ConnesP, AlexyT, DetterichJ, RomanaM, Hardy-DessourcesMD, BallasSK. The role of blood rheology in sickle cell disease. Blood Rev. 2016;30(2):111–8.
16.
MohandasN, GallagherPG. Red cell membrane: Past, present, future. Blood. 2008;112(10):3939–48.
17.
CarvalhoFA, de AlmeidaJP, Freitas-SantosT, SaldanhaC. Modulation of erythrocyte acetylcholinesterase activity and its association with G protein-band 3 interactions. J Membr Biol. 2009;228:89–97.
18.
MinettiG, LowPS. Erythrocyte signal transduction pathways and their possible functions. Curr Opin Hematol. 1997;4:116–21.
19.
PantaleoA, FerruE, CartaF, MannuF, GiribaldiG, VonoR, et al. Analysis of changes in tyrosine and serine phosphorylation of red cell membrane proteins induced by P. falciparum growth. Proteomics. 2010;10:3469–79.
20.
MuravyovAV, TikhomirovaIA. Role molecular signaling pathways in changes of red blood cell deformability. Clin Hemorheol Microcirc. 2013;53:45–59.
21.
OonishiT, SakashitaK, UyesakaN. Regulation of red blood cell filterability by Ca2+ influx and cAMP-mediated signaling pathways. Am J Physiol. 1828;273:C1828–C1834.
22.
MuravyovAV, TikhomirovaIA, MimistovaAA, BulaevaSV, ZamishlayevAV, BatalovaEA. Crosstalk between adenylyl cyclase signaling pathway and Ca2+ regulatory mechanism under red blood cell microrheological changes. Clin Hemorheol Microcirc. 2010;45:337–45.
23.
TuviaS, MosesA, GulayevN, LevinS, KorensteinR. Beta-adrenergic agonists regulate cell membrane fluctuations of human erythrocytes. J Physiol. 1999;516(Pt 3):781–92.
24.
SpragueRS, EllsworthML, StephensonAH, LonigroAJ. Participation of cAMP in a signal-transduction pathway relating erythrocyte deformation to ATP release. Cell Physiology. 1158;281:C1158–C1164.
25.
AdderleySP, DufauxEA, SridharanM, BowlesEA, HansonMS, StephensonAH, et al. Iloprost- and isoproterenol-induced increases in cAMP are regulated by different phosphodiesterases in erythrocytes of both rabbits and humans. Am J Physiol Heart Circ Physiol. 2009;296(5):H1617–24.
26.
AdderleySP, SridharanM, BowlesEA, StephensonAH, EllsworthML, SpragueRS. Protein kinases A and C regulate receptor-mediated increases in cAMP in rabbit erythrocytes. Am J Physiol Heart Circ Physiol. 2010;298:H587–H593.
27.
Sowemimo-CokerSO, TurnerP. The effect of pentoxifylline on filterability of normal red blood cells and their adhesiveness to cultured endothelial cells. Eur J Clin Pharmacol. 1985;29(1):55–9.
28.
SeiffgeD, BertholdR, BertholdF. Effect of pentoxifylline on sickle cell thalassaemia: Haemorheological and clinical results. Klin Wochenschr. 1983;61:1159.
29.
SakaiT, OkadaJ, HaraM, OgashiwaM, TakeuchiK. Red cell deformability in patients with cerebral vasospasm. Int J Clin Pharmacol Ther Toxicol. 1985;23:79.
30.
KoulBL, NordhasO, SonnenfeldT, EkestromS. The effect of pentoxifylline on impaired red cell deformability following open-heart surgery. Scand J Thor Cardiovasc Surg. 1984;18:129.
31.
LingE, DanilovYN, CohenCM. Modulation of red cell band 4.1 function by cAMP-dependent kinase and protein kinase C phosphorylation. J Biol Chem. 1988;263:2209–16.
32.
ChenL, BrownJW, MokYF, HattersDM, McKnightCJ. The allosteric mechanism induced by protein kinase A (PKA) phosphorylation of dematin (band 4.9). J Biol Chem. 2013;288:8313–20.
33.
EmeryAC, EidenMV, EidenLE. A new site and mechanism of action for the widely used adenylate cyclase inhibitor SQ22,536. Mol Pharmacol. 2013;83:95–105.
34.
BaskurtOK, BoynardM, CokeletGC, ConnesP, CookeBM, ForconiS, LiaoF, HardemanMR, JungF, MeiselmanHJ, NashG, NemethN, NeuB, SandhagenB, ShinS, ThurstonG, WautierJL; International Expert Panel for Standardization of Hemorheological Methods. New guidelines for hemorheological laboratory techniques. Clin Hemorheol Microcirc. 2009;42(2):75–97.
35.
MeramE, YilmazBD, BasC, AtacN, YalcinO, MeiselmanHJ, BaskurtOK. Shear stress-induced improvement of red blood cell deformability. Biorheology. 2013;50:165–76.
36.
BaskurtOK, HardemanMR, UyukluM, UlkerP, CengizM, NemethN, et al. Parametrization of red blood cell elongation index-shear stress curves obtained by ektacytometry. Scand J Clin Lab Invest. 2009;69:777–88.
37.
BaskurtOK, MeiselmanHJ. Data reduction methods for ektacytometry in clinical hemorheology. Clin Hemorheol Microcirc. 2013;54:99–107.
38.
EhrlyAM. Improvement of the flow properties of blood: A new therapeutical approach in occlusive arterial disease. Angiology. 1976;27(3):188–96.
39.
AmbrusJL, AnainJM, AnainSM, AnainPM, AnainJMJr, StadlerS, MitchellP, BrobstJA, CobertBL, SavitskyJP. Dose-response effects of pentoxifylline on erythrocyte filterability: Clinical and animal model studies. Clin Pharmacol Ther. 1990;48(1):50–6.
40.
SullivanGW, CarperHT, NovickWJ, MandellGL. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infection and Immunity. 1988;56(7):1722–9.
41.
FrostML, TreadwellP. Treatment of sickle cell leg ulcers with pentoxifylline. Int J Dermatol. 1990;29(5):375–6.
42.
AltmanIA, KleinfelderRE, QuigleyJG, EnnisWJ, MinnitiJP. A treatment algorithm to identify therapeutic approaches for leg ulcers in patients with sickle cell disease. Int Wound J. 2016;13:1315–24.
43.
SacerdoteA. Treatment of homozygous sickle cell disease with pentoxifylline. J Natl Med Assoc. 1999;91:466–70.
44.
SchneiderR. Results of hemorheologically active treatment with pentoxifylline in patients with cerebrovascular disease. Angiology. 1989;40(11):987–93.
45.
EhrlyAM. The effect of pentoxifylline on the deformability of erythrocytes and on the muscular oxygen pressure in patients with chronic arterial disease. J Med. 1979;10(5):331–8.
46.
SloczynskaK, KozkaM, PekalaE, MarchewkaA, MaronaH. In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous disease. Acta Biochim Pol. 2013;60(1):129–35.
47.
CummingsDM, BallasSK. Effects of pentoxifylline and metabolite on red blood cell deformability as measured by ektacytometry. Angiology. 1990;41(2):118–23.
48.
CummingsDM, BallasSK, EllisonMJ. Lack of effect of pentoxifylline on red blood cell deformability. J Clin Pharmacol. 1992;32:1050–3.
49.
MuravyovAV, TikhomirovaIA. Role Ca2+ in mechanisms of the red blood cells microrheological changes. In:
IslamM, editor. Calcium Signaling. Advances in Experimental Medicine and Biology vol 740. Dordrecht: Springer; 2012. pp. 1017–1038.
50.
SwislockiNI, TierneyJM. Prevention by pentoxifylline of transient Ca2+ accumulation and transglutaminase. J Clin Pharmacol. 1991;31:531–6.
51.
SeidlerNW, SwislockiNI. The effects of pentoxifylline on the plasma membrane Ca2+ ATPase in age-separated rat and human erythrocytes. J Clin Pharmacol. 1992;32:332–7.
52.
ElloryJC, CullifordSJ, HorwitzER, MojiminiyiFBO, StuartJ. Oxpentifylline-induced inhibition of calcium entry into human erythrocytes. Clin Hemorheol. 1994;14:545–55.
53.
AmbrusJL, MekyN, StadlerS, SillsRH, GastparH, RaposaT. Studies on the vasoocclusive crisis of sickle cell disease IV. Mechanism of action of pentoxifylline (Trental). J Med. 1988;19(2):67–88.
54.
JacksonEK, KoehlerM, MiZ, DubeyRK, TofovicSP, CarcilloJA, et al. Possible role of adenosine deaminase in vaso-occlusive diseases. J Hypertens. 1996;14(1):19–29.
55.
MahaffeyKW, PumaJA, BarbagelataNA, DiCarliMF, LeesarMA, BrowneKF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction Study of Adenosine (AMISTAD) Trial. J Am Coll Cardiol. 1999;34(6):1711–20.
ZhangY, XiaY. Adenosine signaling in normal and sickle erythrocytes and beyond. Microbes Infect. 2012;14(10):1–19.
58.
KeeferJR, SchneidereithTA, MaysA, PurvisSH, DoverGJ, SmithKD. Role of cyclic nucleotides in fetal hemoglobin induction in cultured CD34+cells. Experimental Hematology. 2006;34:1150–60.
59.
BhanuNV, LeeYT, OnealPA, GanttNM, AerbajinaiW, NoelP, et al. Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives. Biochimica et Biophysica Acta. 2008;1782:504–10.
60.
ZhangY, DaiY, WenJ, ZhangW, GrenzA, SunH, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 2011;17(1):79–86.
61.
WallaceKL, LindenJ. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 2010;116(23):5010–20.
62.
La CellePL. Pathologic erythrocytes in the capillary microcirculation. Blood Cells. 1975;1:269.
CanalliAA, Franco-PenteadoCF, TrainaF, SaadSTO, CostaFF, ConranN. Role for cAMP-protein kinase A signalling in augmented neutrophil adhesion and chemotaxis in sickle cell disease. European Journal of Haematology. 2007;79:330–7.
65.
ZennadiR, De CastroL, EylerC, XuK, KoM, TelenMJ. Role and regulation of sickle red cell interactions with other cells: ICAM-4 and other adhesion receptors. Transfusion Clinique et Biologique. 2008;15:23–28.
66.
BariagaberAK, WhalenMM. Decreased adenylyl cyclase and cAMP-dependent protein kinase activities inhibit the cytotoxic function of human natural killer cells. Human Immunology. 2003;64:866–73.
67.
DaviesSP, ReddyH, CaivanoM, CohenP. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95–105.
68.
LochnerA, MoolmanJA. The Many Faces of H A Review. Cardiovascular Drug Reviews. 2006;24(3-4):261–74.
69.
BaskurtOK, YalcinO, MeiselmanHJ. Hemorheology and vascular control mechanisms. Clin Hemorheol Microcirc. 2004;30:169–78.
70.
LouderbackJG, BallasSK, Kim-ShapiroDB. Sickle hemoglobin polymer melting in high concentration phosphate buffer. Biophys J. 1999;76(4):2216–22.
71.
ShapiroDB, EsquerraRM, GoldbeckRA, BallasSK, MohandasN, KligerDS. Carbon monoxide religation kinetics to hemoglobin S polymers following ligand photolysis. J Biol Chem. 1995;270(44):26078–85.
